MedTrace Logo

Use of CGM in Kidney Transplant Recipients

NCT04783441 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-01-29

No results posted yet for this study

Summary

The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.

Conditions

  • Kidney Transplant; Complications
  • Diabetes Mellitus, Type 2
  • Insulin Dependent Diabetes

Interventions

DEVICE

Dexcom G6

access to continuous glucose monitoring in the Dexcom G6 arm 24/7

DEVICE

Dexcom G6 blinded sensor

retrospective access to continuous glucose profile after 10 days of wear

Sponsors & Collaborators

  • DexCom, Inc.

    collaborator INDUSTRY

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Ling Chen, MD · UCDavis Transplant Nephrology

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04783441 on ClinicalTrials.gov